{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:29Z","timestamp":1787067449056,"version":"build-2736575974"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Pfizer Pharmaceuticals Korea Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this article is to assess the safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in routine clinical settings in Korea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a prospective, multi-centre post-marketing surveillance study. Data were prospectively collected within 6\u2009months after the start of tofacitinib therapy. Safety was evaluated based on the presence of adverse events (AEs) observed in patients who received at least one dose of tofacitinib. Effectiveness was assessed according to the proportion of patients who achieved low disease activity and remission, American College of Rheumatology 20 criteria (ACR20), European League Against Rheumatism (EULAR) response, and change of Disease Activity Score in 28 Joints (DAS28).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incidence rates [patients with events per 100 patient-years (PY)] of AEs and serious AEs were 56.92 and 10.69, respectively. Regarding AEs of special interest, the incidence rates were 4.33 per 100 PY for serious infections and infestations, 5.78 per 100 PY for herpes zoster, no event of tuberculosis, 0.29 per 100 PY for malignancy, 0.29 per 100 PY for venous thromboembolism (one event of deep vein thrombosis and no event of pulmonary embolism), 0.87 per 100 PY for major adverse cardiovascular event, and 0.58 per 100 PY for mortality. Moreover, \u223c40.48% and 21.60% of patients achieved low disease activity and remission of DAS28-erythrocyte sedimentation rate. The EULAR response was classified as good responders with 39.12% in the DAS28-erythrocyte sedimentation rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The benefit\/risk profile of tofacitinib in adult patients with rheumatoid arthritis in routine clinical settings in Korea was similar to long-term clinical trial data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roac136","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T17:33:18Z","timestamp":1668879198000},"page":"1087-1096","source":"Crossref","is-referenced-by-count":5,"title":["Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: A post-marketing surveillance study"],"prefix":"10.1093","volume":"33","author":[{"given":"Ji Hyeon","family":"Ju","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Kyoung","family":"Sung","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-young","family":"Jo","sequence":"additional","affiliation":[{"name":"Pfizer Pharmaceuticals Korea Ltd , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja-Young","family":"Jeon","sequence":"additional","affiliation":[{"name":"Pfizer Pharmaceuticals Korea Ltd , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Jeong","family":"Yoo","sequence":"additional","affiliation":[{"name":"Pfizer Pharmaceuticals Korea Ltd , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-1208","authenticated-orcid":false,"given":"Eun Bong","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul National University , Seoul,","place":["Korea"]},{"name":"Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"2024101109361500500_R1","first-page":"S128","article-title":"Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis","volume":"20","author":"Allan","year":"2014","journal-title":"Am J Manag Care"},{"key":"2024101109361500500_R2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00296-017-3925-9","article-title":"Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization","volume":"38","author":"Soyoung","year":"2018","journal-title":"Rheumatol Int"},{"key":"2024101109361500500_R3","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/14397595.2019.1682776","article-title":"Epidemiological characteristics of rheumatoid arthritis in Japan: prevalence estimates using a nationwide population-based questionnaire survey","volume":"30","author":"Kojima","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2024101109361500500_R4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Josef","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024101109361500500_R5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2010.25.1.1","article-title":"Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis","volume":"25","author":"Steven","year":"2010","journal-title":"Korean J Intern Med"},{"key":"2024101109361500500_R6","first-page":"15","article-title":"European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib","volume":"14","author":"Pawe\u0142","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"2024101109361500500_R7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.gastre.2019.03.012","article-title":"Efficacy of tofacitinib treatment in ulcerative colitis","volume":"42","author":"Julian","year":"2019","journal-title":"Gastroenterol Hepatol (English Edition)"},{"key":"2024101109361500500_R8","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024101109361500500_R9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2024101109361500500_R10","doi-asserted-by":"crossref","DOI":"10.1186\/ar2745","article-title":"Outcome measures in inflammatory rheumatic diseases","volume":"11","author":"Fransen","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2024101109361500500_R11","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024101109361500500_R12","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/1756-185X.13516","article-title":"Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: post-hoc analyses of pooled clinical study data","volume":"22","author":"Eun-Bong","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2024101109361500500_R13","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"Van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024101109361500500_R14","article-title":"Revision of Infectious Disease Control and Prevention Act Including Herpes Zoster Vaccination National Immunization Program","author":"MedicateNews","year":"2020"},{"key":"2024101109361500500_R15","first-page":"1","article-title":"Shingles vaccination among adults aged 60 and over: United States, 2018","author":"Terlizzi","year":"2020","journal-title":"NCHS Data Brief"},{"key":"2024101109361500500_R16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/acr.24010","article-title":"Live zoster vaccine in patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, or adalimumab with methotrexate: a post hoc analysis of data from a phase IIIb\/IV randomized study","volume":"72","author":"Calabrese","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024101109361500500_R17","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024101109361500500_R18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1047-2797(00)00057-0","article-title":"Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men","volume":"10","author":"Shannon","year":"2000","journal-title":"Ann Epidemiol"},{"key":"2024101109361500500_R19","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/acr.23930","article-title":"Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase III and long-term extension studies","volume":"71","author":"Gladman","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024101109361500500_R20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024101109361500500_R21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"2024101109361500500_R22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac136\/47510101\/roac136.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/6\/1087\/59718876\/roac136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/6\/1087\/59718876\/roac136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T05:36:30Z","timestamp":1728624990000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/6\/1087\/6833487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,11,19]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac136","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2022,11,19]]}}}